Clinical Trial Update: Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating second-line therapy with ERIbulin followed by capecitabine or the reverse sequence in HER2-negative metastatic breast cancer pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN